Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Single Rapid Test Detects Known and Unknown Pathogens

By LabMedica International staff writers
Posted on 10 Nov 2014
Diagnostic technology developed for rapid detection of pathogens in the wounds of soldiers has been licensed to a private company that intends to use it to create new medical laboratory tests.

The Lawrence Livermore Microbial Detection Array (LLMDA) is designed to improve on two pathogen identification techniques: Polymerase chain reaction (PCR) analysis and DNA sequencing. More...
PCR diagnostic techniques can process no more than 50 DNA signatures at one time and the likelihood of discovering new species are low with PCR. The new technology is capable of identifying thousands of bacteria and viruses in a single test.

Scientists at the Lawrence Livermore National Laboratory (LLNL; Livermore, CA, USA) developed the LLMDA. The process begins by purifying DNA or ribonucleic acid (RNA) from a blood or stool sample. The purified DNA or RNA is labeled with a fluorescent dye, and then pipetted onto the microarray which sits on top of an incubator heated to 42 °C. The microarray contains nearly 400,000 probes arranged in a checkerboard pattern on a 2.5 × 7.5-cm glass slide. Scientists examine these probes with a fluorescent scanner and analysis software. The microarray’s checkerboard has several dozen squares for each of the thousands of organisms sequenced to date. That allows it to simultaneously examine multiple regions from each organism.

From a study that evaluated 124 wound samples from 44 soldiers injured in Iraq and Afghanistan using LLDMA, the scientists found certain bacteria, such as Pseudomonas species and Acinetobacter baumannii, which are common hospital-related infections, to be associated with wounds that did not heal successfully. Bacteria often related to the gastrointestinal system, such as Escherichia coli and Bacteroides species, were also often found in wounds that did heal successfully. The test was able to detect within 24 hours any virus or bacteria that has been sequenced and included among the array's probes.

The LLNL scientists are already building on the capacity of this microbial array. They are currently testing a next-generation LLMDA that contains 2.1 million probes representing about 178,000 sequences from 5,700 viruses and 785,000 sequences from thousands of bacteria. The new version also includes about 237,000 sequences from hundreds of fungi and about 202,000 sequences from 75 protozoa. Lawrence Livermore National Laboratory has licensed its microbial detection array technology to MOgene LC (St. Louis, MO, USA).

Related Links:
Lawrence Livermore National Laboratory
MOgene LC 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.